| Dr Michael J Rogal, MD | |
|
600 Oxford Dr, Suite 200, Monroeville, PA 15146-2355 | |
| (412) 858-0380 | |
| Not Available |
| Full Name | Dr Michael J Rogal |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 600 Oxford Dr, Monroeville, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669479887 | NPI | - | NPPES |
| 0008446440001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD021086E (Pennsylvania) | Primary |
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Rogal, MD 200 Lothrop St, Room 9055, Pittsburgh, PA 15213-2536 Ph: (412) 647-3087 | Dr Michael J Rogal, MD 600 Oxford Dr, Suite 200, Monroeville, PA 15146-2355 Ph: (412) 858-0380 |
News Archive
DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 5 days ago
Dr. David C Neuschwander, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2550 Mosside Blvd, Ste. 405, Monroeville, PA 15146 Phone: 412-373-1600 Fax: 412-373-2406 | |
Dr. Gregory Joseph Purnell Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2550 Mosside Blvd, Suite 405, Monroeville, PA 15146 Phone: 412-373-1600 Fax: 412-373-4197 | |
Jeanne Doperak, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 Oxford Dr, Monroeville, PA 15146 Phone: 412-372-1600 | |
Dr. Gregory L Hung, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2550 Mosside Blvd, Suite 405, Monroeville, PA 15146 Phone: 412-373-1600 Fax: 412-373-2406 | |
Dr. Michael Maher, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2580 Haymaker Rd Ste 104, Monroeville, PA 15146 Phone: 412-373-1600 | |
Dr. Arnold S Broudy, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2550 Mosside Blvd, Ste 405, Monroeville, PA 15146 Phone: 412-373-1600 | |
Dr. Stephen Charles Martinkovich, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2550 Mosside Blvd Ste 405, Monroeville, PA 15146 Phone: 412-359-6501 Fax: 412-373-4197 |